At the news
? NEUTRALIMPACT 4/10 CLUSTER filed Feb 24, 2026 at 19:00 ET
Seven Vertex Pharmaceuticals executives sold shares in the past week, including open-market sales totaling $2.3M and tax-related share withholdings worth $7.3M. The activity is primarily driven by routine tax settlements following vesting events, not discretionary selling.
- Five executives conducted open-market sales totaling $2.31M in the past two days.
- All seven insiders also surrendered shares for tax withholding totaling $7.31M, including CEO Reshma Kewalramani ($2.42M) and Executive Chairman Jeffrey Leiden ($1.72M).
- Tax withholdings accounted for ~76% of total transaction value in the cluster.
- Total economic value of open-market sales is 0.0019% of VRTX's $122.5B market cap, immaterial in scale.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access